AAM submitted comments to CMS, highlighting the extent and ways in which Part D sponsors and their PBMs engage in practices that favor, intentionally or unintentionally, more expensive reference drugs ...
Alvotech and Teva announced that the Food and Drug Administration has accepted for review Biologics License Applications for AVT05, Alvotech’s proposed biosimilar to Simponi and Simponi Aria ...